Ebru Sahin Kehribar

Ebru Sahin Kehribar

Auto-generated profile, based on publicly available information

Ebru Sahin Kehribar

Synbiotik Biotechnology and Biomedical Technology, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Heliyon
Verified
Journal Article
Open access
AHAlireza Hanifehnezhad
Alireza Hanifehnezhad
EKEbru Şahin Kehribar
Ebru Şahin Kehribar
SÖSıdıka Öztop
Sıdıka Öztop
ASAli Sheraz
Ali Sheraz
SKSerkan Kasırga
Serkan Kasırga
AOAykut Ozkul
Aykut Ozkul
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently a global pandemic with unprecedented public health, economic and social impact. The development of effective mitigation strategies, therapeutics and vaccines relies on detailed genomic and biological characterization of the regional viruses. This study was carried out to isolate SARS-CoV-2 viruses circulating in Anatolia, and to investigate virus propagation in frequently-used cells and experimental animals. We obtained two SARS-CoV-2 viruses from nasopharngeal swabs of confirmed cases in Vero E6 cells, visualized the virions using atomic force and scanning electron microscopy and determined size distribution of the particles. Viral cytopathic effects on Vero E6 cells were initially observed at 72 h post-inoculation and reached 90% of the cells on the 5th day. The isolates displayed with similar infectivity titers, time course and infectious progeny yields. Genome sequencing revealed the viruses to be well-conserved, with less than 1% diversity compared to the prototype virus. The analysis of the viral genomes, along with the available 62 complete genomes from Anatolia, showed limited diversity (up to 0.2% on deduced amino acids) and no evidence of recombination. The most prominent sequence variation was observed on the spike protein, resulting in the substitution D614G, with a prevalence of 56.2%. The isolates produced non-fatal infection in the transgenic type I interferon knockout (IFNAR−/-) mice, with varying neutralizing antibody titers. Hyperemia, regional consolidation and subpleural air accumulation was observed on necropsy, with similar histopathological and immunohistochemistry findings in the lungs, heart, stomach, intestines, liver, spleen and kidneys. Peak viral loads were detected in the lungs, with virus RNA present in the kidneys, jejunum, liver, spleen and heart. In conclusion, we characterized two local isolates, investigated in vitro growth dynamics in Vero E6 cells and identified IFNAR−/− mice as a potential animal model for SARS-CoV-2 experiments.

19 February 2021 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
EKEbru Sahin Kehribar
Ebru Sahin Kehribar
MIMusa Efe Isilak
Musa Efe Isilak
EBEray Ulas Bozkurt
Eray Ulas Bozkurt
JAJozef Adamcik
Jozef Adamcik
RMRaffaele Mezzenga
Raffaele Mezzenga
USUrartu Seker
Urartu Seker
Glycosylation is a crucial post-translational modification for a wide range of functionalities. Adhesive protein-based biomaterials in nature rely on heavily glycosylated proteins such as spider silk and mussel adhesive proteins. Engineering protein-based biomaterials genetically enables desired functions and characteristics. Additionally, utilization of glycosylation for biomaterial engineering can expand possibilities by including saccharides to the inventory of building blocks. Here, de novo glycosylation of Bacillus subtilis amyloid-like biofilm protein TasA using a Campylobacter jejuni glycosylation circuit is proposed to be a novel biomaterial engineering method for increasing adhesiveness of TasA fibrils. A C. jejuni glycosylation motif is genetically incorporated to tasA gene and expressed in Escherichia coli containing the C. jejuni pgl protein glycosylation pathway. Glycosylated TasA fibrils indicate enhanced adsorption on the gold surface without disruption of fibril formation. Our findings suggest that N-linked glycosylation can be a promising tool for engineering protein-based biomaterials specifically regarding adhesion.

1 March 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
EYEsra Yuca
Esra Yuca
EKEbru Şahin Kehribar
Ebru Şahin Kehribar
USUrartu Seker
Urartu Seker

20 January 2022 in Turkish Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
ABAliye Bastug
Aliye Bastug
HBHurrem Bodur
Hurrem Bodur
USUrartu Seker
Urartu Seker
NFNazlıcan Filazi
Nazlıcan Filazi
OAOmer Aydos
Omer Aydos
AOAykut Ozkul
Aykut Ozkul
Background: There is a knowledge gap about the characteristics of neutralizing antibody (NAb) response in patients who recovered COVID-19. In this study, it is aimed to elucidate the factors affecting the presence and titers of antibodies up to 30-days after onset. Material and methods: A total of 129 laboratory-confirmed COVID-19 patients were enrolled. Clinical data were obtained retrospectively. SARS-CoV-2 specific NAb, IgM, and IgG antibody responses were analyzed. Results: SARS-CoV-2 specific NAb, IgM and IgG, were detected at the time of hospital discharge in 60.5%, 30.2%, and 51.9% of the patients, respectively. The median time for obtaining serum samples for antibody tests after symptoms’ onset was 11 days. The median titer of neutralizing antibody (SN 50 ) was significantly higher in severe patients (25 vs. 7.5, p=0.009). Of the 23 severe patients, 52.2% (n=12) had higher NAb titers (i.e., SN 50 ≥1:25) when compared to that in non-severe patients (OR=2.89; 95%CI=1.15–7.28, p=0.021), yet, the potential effect of follow-up time on NAb status and titers could not be ruled out. Conclusions: The presence of antibody response is not the only determinative factor for recovery. The presence and higher titers of NAb were detected more in severe patients than their non-severe counterparts. Survival analysis suggested that this difference could at least be partially explained by the length of follow-up through antibody testing (at discharge) after symptoms’ onset.

23 July 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
RARecep Erdem Ahan
Recep Erdem Ahan
AHAlireza Hanifehnezhad
Alireza Hanifehnezhad
EKEbru Şahin Kehribar
Ebru Şahin Kehribar
TOTuba Cigdem Oguzoglu
Tuba Cigdem Oguzoglu
KFKatalin Foldes
Katalin Foldes
USUrartu Seker
Urartu Seker
COVID-19 pandemic effected more than 180 million people around the globe causing more than four million deaths as of July 2021. Sars-CoV-2, the new coronavirus, has been identified as the primary cause of the infection. The number of vaccinated people is increasing however prophylactic drugs are highly demanded to ensure a secure social contact. There have been a number of drug molecules repurposed to fight against Sars-CoV-2, however the proofs for the effectiveness of these drug candidates is limited. Here we demonstrated griffithsin (GRFT), a lectin protein, to block the entry of the Sars-CoV2 into the Vero6 cell lines and IFNAR-/-mouse models by attaching to spike protein of the Sars-CoV-2. Given the current mutation frequency of the Sars-CoV-2 we believe that GRFT protein-based drugs will have a high impact in preventing the transmission both on Wuhan strain as well as any other emerging variants including delta variant causing high speed spread of COVID-19.

6 July 2026 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
SSSenem Sen
Senem Sen
ASAslı Semerci
Aslı Semerci
RARecep Erdem Ahan
Recep Erdem Ahan
COCemile Elif Ozcelik
Cemile Elif Ozcelik
EDElif Duman
Elif Duman
USUrartu Seker
Urartu Seker